zurig说明书

Instructions:

Generic name: Febuxostat

Full names: febuxostat, febuxostat, feburic, febuxostat, uloric, zurig

Indications: It is suitable for the long-term treatment of hyperuricemia in patients with gout, but it is not recommended for use in patients with asymptomatic hyperuricemia.

Specifications: 40mg*8s*2 plates

Usage and dosage:

The recommended oral starting dose is 40 mg, once a day. If the blood uric acid level is still not less than 6 mg/dL (360 μg) after two weeks, it is recommended to increase the dose to 80 mg, once a day. The maximum dosage is 120 mg/day. This dose is effective for patients with higher blood uric acid levels.

After 6 months of treatment:

(1) If the serum uric acid level remains between 240 umol/l and 360 umol/l, maintain febuxostat 40 mg/day treatment.

(2) If the blood uric acid level is higher than 360 umol/l, increase the dose of fexostatin by 60 mg/day, up to a maximum of 80 mg/day, and monitor blood uric acid, liver and kidney function regularly.

(3) If the blood uric acid level is lower than 240 umol/l, the dose of febuxostat can be reduced to 20 mg/day and the treatment can be maintained for 6 months.

Adverse reactions:

1. Abnormal liver function, nausea, joint pain, rash, diarrhea and dizziness, among which abnormal liver function is a serious adverse reaction;

2. Some literature reports that common adverse reactions include upper respiratory tract infection, muscle and skeletal muscle and related tissue abnormalities, headache, edema, pulmonary infection, abnormal sensation and hypoesthesia, etc.

3. The incidence of serious adverse reactions is cardiovascular disease, including non-fatal myocardial infarction, non-fatal stroke and cardiovascular death, which is higher than that of allopurinol. The incidence of cardiovascular adverse reactions is not related to the dose of febuxostat and does not increase with the extension of treatment time.

Things to note:

1. Gout attack: In the early stage of taking febuxostat, it may cause gout attack. This is caused by the change in uric acid level and the mobilization of urate deposited in the tissue. At this time, there is no need to stop taking the medicine. Taking nonsteroidal anti-inflammatory drugs or colchicine at the same time during the initial use of febuxostat can prevent gout attacks.

2. Cardiovascular events: So far, the causal relationship between this drug and cardiovascular thrombotic events has not been determined, but the febuxostat 80mg group had more cardiovascular events, so symptoms and signs of myocardial infarction and cardiovascular death should be monitored when taking the drug.

3. Effects on the liver: Patients who use febuxostat will experience abnormal liver function, such as fatigue, loss of appetite, jaundice, diarrhea, headache, etc. During clinical medication, when abnormal liver function is found in patients, the medication should be discontinued and the possible cause should be determined as much as possible. When the cause is unclear, it is not suitable to use febuxostat in these patients.

4. Secondary hyperuricemia: This drug has not been studied in patients with secondary hyperuricemia, so its use (febuxostat) is not recommended for patients with secondary hyperuricemia.